Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.

Clinical immunology (Orlando, Fla.) - 1 Oct 2018

Jackson Doreen O, Trappey Francois A, Clifton G Travis, Vreeland Timothy J, Peace Kaitlin M, Hale Diane F, Litton Jennifer K, Murray James L, Perez Sonia A, Papamichail Michael, Mittendorf Elizabeth A, Peoples George E

Abstract excerpt

Immunotherapy, using peptide-based cancer vaccines is being studied to assess its potential in breast cancer. Trials of HLA-restricted peptide vaccines have been difficult to enroll given HLA subtype restrictions. It is necessary to determine the prognostic significance of HLA-status in breast cancer if patients who are ineligible to receive a vaccine due to their HLA-status are used as controls. The impact of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Granulocyte-Macrophage Colony-Stimulating Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Receptor, ErbB-2

Share to Research Design

Share to Vaccination

Share to Vaccines, Subunit

Source

Identifiers

PMID: 30025819
DOI: 10.1016/j.clim.2018.06.008

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.PMID 30025819Read ↗

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccineSemantic proximity Read ↗

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Semantic proximity Read ↗

Roles of HLA-G/KIR2DL4 in Breast Cancer Immune MicroenvironmentSemantic proximity Read ↗

Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.Semantic proximity Read ↗

Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expressionSemantic proximity Read ↗

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational StudySemantic proximity Read ↗

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Semantic proximity Read ↗

Implication of Soluble HLA-G and HLA-G +3142G/C Polymorphism in Breast Cancer Patients Receiving Adjuvant Therapy in Tanzania.Semantic proximity Read ↗

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.Semantic proximity Read ↗

CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.Semantic proximity Read ↗

Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.Semantic proximity Read ↗

Facts and controversies in the use of trastuzumab in the adjuvant setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.